KCM
KRON

Kennedy Capital Management’s Kronos Bio KRON Stock Holding History

Kennedy Capital Management’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-149,251
Closed -$142K – 675
2024
Q4 		$142K Buy
149,251
+12,007
+9% +$11.3K ﹤0.01% 666
2024
Q3 		$137K Buy
137,244
+19,607
+17% +$21.7K ﹤0.01% 682
2024
Q2 		$146K Buy
117,637
+2,576
+2% +$2.62K ﹤0.01% 687
2024
Q1 		$150K Buy
115,061
+6,832
+6% +$7.79K ﹤0.01% 713
2023
Q4 		$135K Sell
108,229
-830
-0.8% -$918 ﹤0.01% 678
2023
Q3 		$142K Buy
109,059
+2,563
+2% +$4.14K ﹤0.01% 661
2023
Q2 		$183K Buy
106,496
+90,472
+565% +$144K ﹤0.01% 656
2023
Q1 		$23.4K Buy
+16,024
New +$30.7K ﹤0.01% 617

Other funds holding KRON

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.65B AUM 16.42% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Kennedy Capital Management's KRON Position: Q1 2025 in Review

Kennedy Capital Management sold out of Kronos Bio (KRON) in Q1 2025, closing a stake of 149,251 shares — an estimated $142K sold.

Kennedy Capital Management first reported a position in KRON in Q1 2023 and held it in 8 quarters. The position peaked at $183K in Q2 2023. 47 funds tracked by Wall St. Rank hold KRON as of Q1 2025.

  • Kennedy Capital Management reported no remaining Kronos Bio position as of Q1 2025 after selling out during the quarter.
  • Kennedy Capital Management sold 149,251 Kronos Bio shares in Q1 2025, an estimated $142K.
  • Kennedy Capital Management first reported a position in Kronos Bio in Q1 2023 and held it in 8 quarters.
  • Kennedy Capital Management's Kronos Bio position peaked at $183K in Q2 2023.
  • 47 funds tracked by Wall St. Rank held Kronos Bio as of Q1 2025.

Based on Kennedy Capital Management's 13F filing for Q1 2025, filed 13 May 2025.